Compare Main Street Capital Corporation (MAIN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs TransMedics Group Inc — how do they compare? Main Street Capital Corporation trades at $54.92 (market cap $5.08B), while TransMedics Group Inc trades at $74.92 (market cap $2.54B). The key difference: Main Street Capital Corporation is far larger — about 2× TransMedics Group Inc's market cap, and Main Street Capital Corporation pays a 8.02% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MAIN | TMDX | |
|---|---|---|
Market Cap | $5.08B | $2.54B |
Sector | Financials | Technology |
52-Week High | $67.54 | $150.42 |
52-Week Low | $49.63 | $61.99 |
Dividend Yield | 8.02% | — |
Enterprise Value | — | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.59, down 1.41% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.93, missing expectations of $1.01, while Q4 2025 beat estimates. Revenue for 2025 was $591.85M with a net income margin of 83.36%, though 2026 projections show a decline to $526M. Analysts maintain a consensus price target of $57.75 with a 'Hold' rating predominance. Recent news highlights MAIN's dividend sustainability amid softening earnings.
MAIN offers a stable dividend yield but faces earnings pressure and revenue decline projections for 2026. The stock's valuation appears reasonable with a P/E of 11.66, yet investor caution is warranted due to mixed earnings performance and potential headwinds from Fed rate cuts impacting BDC earnings. Upside exists if the company meets or exceeds future EPS expectations, supported by its internal management cost advantage.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
